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Abstract: 
     The suitability of chitosan (non-crosslinked and 
crosslinked by glutaraldehyde) for colonic drug delivery 
was assessed by incubation of chitosan films in human 
faecal slurry and assessment of the film’s disappearance 
with time.  It was found that non-crosslinked chitosan, 
was digested by colonic bacteria, but crosslinked chitosan 
was not.   
 
Introduction: 
     Polysaccharides, such as amylose, guar gum, pectin 
and chitosan (Basit, 2005) are increasingly being 
investigated for the delivery of drugs to the colon.  An 
essential feature of these potential drug delivery systems 
is non-degradation by small intestinal digestive enzymes, 
but digestion by the enzymes produced by the colonic 
microflora.  Thus, they should prevent drug release in the 
small intestine, and allow drug release in the colon.  
Chitosan is being investigated as it is biodegradable, 
biocompatible and has low oral toxicity.  There are 
several investigations into the suitability of chitosan for 
colonic delivery (Tozaki et al., 1997; Zambito et al., 
2005) but all investigations to date have used rat caecal 
contents to assess the colonic release.  This may not be 
directly comparable to human colonic contents or faecal 
material.  Work has shown that chitosan is degraded to 
different extents in different species, such as dogs 
(Okamoto et al., 2001), rabbits, hens and sheep (Hirano et 
al., 1990).  Hence, it cannot be assumed that chitosan is 
sufficiently digested by human colonic microflora.  
Before investigating the potential of chitosan as a colonic 
delivery system, it is essential to assess whether the 
human colonic microflora is capable of digesting the 
material.  The process of microfloral digestion is one of 
fermentation, in which the anaerobic bacteria break down 
substrates to produce energy.   
 
     Chitosan, a weak base (pKa 6.2-7.0), is a [(1,4) 2 
amino-2-deoxy-beta-d-glucan], whose structure is shown 
in Figure 1.  It is obtained by the alkaline deacetylation of 
chitin, which is the second most abundant polysaccharide 
in nature, after cellulose.  It is found in the exoskeletons 
of crustaceans and insects which are not substantial 
components of the human diet.  Human colonic bacteria 
may not therefore normally produce enzymes capable of 
digesting chitin and chitosan.  The latter is structurally 
similar to cellulose, which has been shown not to be 
fermented in the human colon.   
 
Figure 1 Structure of Chitosan 
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     When formulated as a drug delivery vehicle, chitosan 
is often crosslinked by agents such as glutaraldehyde, in 
order to reduce the swelling and dissolution in aqueous 
media.  Examples are microparticles for colonic delivery 
(Rai et al., 2005).  It is not known whether crosslinked 
systems can be degraded by human colonic microflora.   
 
     The aim of this investigation was to therefore assess 
whether chitosan (crosslinked and non-crosslinked) can 
be digested by human colonic bacteria, and thus, whether 
they have potential as colonic delivery systems.  Films of 
chitosan, and crosslinked chitosan, were prepared and the 
film loss in human faecal slurry was determined.   
 
Experimental Methods: 
 
Preparation of Chitosan Films 
     Chitosan of low and high molecular weights (LMW 
Chitosan and HMW Chitosan) (75-85% deacetylated) 
were used.  Solutions of 1.5% w/v chitosan were prepared 
by dissolving in 5% v/v acetic acid with stirring 
overnight. The solution was passed through a 180 µm 
sieve.  Forty millilitres of this solution were poured into 
Teflon plates (9 cm diameter) and dried for 48 hrs at room 
temperature, followed by 24 hr incubation in an oven at 
50
o
C.  The films were removed and stored at room 
temperature in 44% relative humidity (RH).   
 
     To prepare films crosslinked with glutaraldehyde, the 
same method was followed, except for the addition of 
0.30 ml of glutaraldehyde solution (50% v/v) to 150 ml of 
chitosan solution in acetic acid, followed by stirring 
overnight, to allow the crosslinking to occur.  The films 
were cast, dried, removed and stored as before.    
 
Fermentation Studies 
     Preparation of faecal material and all fermentation 
studies were carried out under anaerobic conditions using 
an Electrotek Anaerobic Workstation AW500TG, at a 
temperature of 36.5
o
C, with a relative humidity of 70%.   
 
     The chitosan and crosslinked chitosan films were cut 
into sections, approximately 2.5 cm
2
.  Each section was 
weighed and placed into polyamide mesh bags (Nitex
®
, 
Sefar), with a mesh size of 2000 µm.   
 
     Faecal samples were pooled from three volunteers and 
slurries at a concentration of 10% w/v in freshly boiled 
and cooled phosphate buffered saline (PBS pH 6.8 BP) 
were prepared, by homogenisation, and filtration through 
a 350 µm mesh to remove any unhomogenised material.   
 
     The faecal slurry was placed in 500 ml vessels, in 
which the film-containing mesh bags were suspended.  A 
control vessel, also containing films, was filled with PBS 
pH 6.8 BP.  These vessels were placed on a rocking 
platform.  At 4 and 18 hours, films were removed and 
dried in a hot air oven (50
o
C), overnight.  The films were 
then stored at room temperature at 44% RH, for 24 hours 
after which they were weighed and the weight loss 
calculated.  Each film and condition was studied in 
triplicate.   
 
Results and Discussion: 
     There was a marked difference between the films 
produced with and without crosslinking. The chitosan 
solutions produced translucent white/ yellow films, which 
were somewhat flexible and easily torn.  They had a paper 
like texture.  These films swell in contact with water, but 
did not dissipate.  The addition of crosslinking agent 
glutaraldehyde to the chitosan solutions produced films 
which were translucent and dark brown, and while they 
had flexibility, they were also tougher, with a plastic like 
texture.  These did not swell in contact with water.   
 
     The weight loss of both chitosan and crosslinked (CL) 
chitosan films, after incubation in faecal slurry (10%), and 
control conditions (PBS pH 6.8) for 18 hours is shown in 
the Figure below.  The results for both HMW chitosan 
and LMW chitosan films are shown.   
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    In control conditions, non-crosslinked chitosan shows 
around 50% weight loss at 18 hours.  At 4 hrs, there was 
seen to be less film loss (data not shown).  This can be 
attributed to some dissolution of the chitosan gel, in the 
slightly acidic media of the control and the faecal slurry.  
The pH of the control and the faecal slurry before 
incubation were 6.84 and 6.93 respectively.  After 4 
hours, these had dropped to 6.0 and 6.4, which did not 
change further up to 18 hours.  The drop in pH may be 
responsible for the dissolution of some of the chitosan 
films, especially in the control solution.  In colonic 
conditions, almost complete loss of the low and high 
molecular weight chitosan films was seen.  The extra loss 
of the films is likely to be due to bacterial degradation.  
This film loss in colonic conditions was seen to be almost 
complete at four hours (data not shown) and this may 
suggest that the in vivo site of degradation would be the 
proximal colon, the site most densely populated with 
polysaccharidase producing bacteria.  These results 
confirm that degradation of chitosan by human colonic 
bacteria can occur, and hence it may be suitable for 
development as a colonic drug delivery system.   
 
     In contrast to the non-crosslinked chitosan films, the 
weight loss from crosslinked films occurred to a much 
smaller extent.  There was also no obvious difference 
between the control and faecal incubations, suggesting 
that degradation by colonic bacteria of the crosslinked 
material is minimal. The process of cross-linking may 
render the active sites inaccessible for the enzymes in 
question, and they are unable to use it as a substrate.  
Crosslinked chitosan may not then be suitable for a 
bacterially triggered colonic delivery system   
   
Conclusions: 
     Non-crosslinked chitosan is degraded by the human 
colonic microflora.  It may therefore be a potential 
candidate for colonic drug delivery systems and its 
digestibility in pancreatic enzymes should be assessed in 
further work.   
 
     In contrast to the suitability of non-crosslinked 
chitosan, those films prepared with crosslinked chitosan 
may not be appropriate candidates for colonic delivery 
systems.  It will be important to assess the effects of 
varying the concentration of the crosslinking agents.  The 
effect of other crosslinking agents, such as 
tripolyphosphate, will be investigated in future work.  
 
     These results highlight the potential of using chitosan 
as a microbially triggered colonic delivery system.  
However, they raise concerns for the use of crosslinked 
chitosan and indeed the use of other crosslinked 
polysaccharides for colonic delivery.  
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